>>> US Gapping down

Gapping down
In reaction to earnings/guidance:

EXAS -22.3%, AVNW -18.3%, SMCI -15.8% (also finds no evidence of fraud or misconduct by mgmt or board), EOSE -13.8% (also new customer agreement with City Utilities), MEC -13.2%, ODP -13.1%, CLVT -9.7%, BGS -9.5%, AUDC -9.3%, INNV -7.7%, HMC -7.1%, VTEX -7%, CELH -6.9%, LNTH -6.9%, IRBT -6.8% (also announces restructuring plan, which includes a 16% workforce reduction), CPNG -6.4%, BBAI -6.3%, SWIM -5.8%, MBC -5.8%, RARE -5.1% (also provides DTX401 Phase 3 follow-up data), LUMN -4.2%, NCMI -3.4%, WTTR -3.1%, SMG -2.5%, SUN -2.1%, KGC -2%, SPR -1.9% (provides FCF guidance; also warns substantial doubt about its ability to continue as a going concern), FREY -1.9%, ATHM -1.8%, INFN -1.5%, NHI -1.4%, VSH -1.1%

Select Solar related names showing early weakness following US election:

JKS -17.1%, RUN -17%, FSLR -13.9%, CSIQ -12.7%, TAN -11.1%, SOL -4.9%

Other news:

TNGX -25.5% (reports positive TNG462 clinical data and provides update on PRMT5 development program)
PACS -22.1% (Q3 operating metrics)
NVAX -3.2% (discloses settlement agreement)
CCCC -2.1% (announces that its partner Betta Pharmaceuticals has dosed the first patient in the Phase 1 clinical trial of CFT8919, an orally bioavailable allosteric degrader of EGFR L858R for non-small cell lung cancer, in Greater China)
LXRX -1.7% (announces Sotagliflozin data published)
LGIH -1.5% (reports Oct home sales)
PAAS -1.2% (receives approval for sale of La Arena from Canada)

Analyst comments: